A team of researchers at Children’s Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania (both UAE Partners) are exploring the use of convalescent plasma to treat COVID-19, the disease caused by SARS-CoV-2. David Teachey, MD, who co-leads the Immune Dysregulation Frontier Program at CHOP and is an associate professor of pediatrics at Penn, worked with a multispecialty team to obtain emergency approval from the FDA for the experimental approach. Read more on Cornerstone. https://lnkd.in/e_ZTdKE
